Compare REAL & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REAL | VNDA |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | United States |
| Employees | N/A | 533 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 373.4M |
| IPO Year | 2019 | 2005 |
| Metric | REAL | VNDA |
|---|---|---|
| Price | $9.21 | $6.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $17.00 | $14.90 |
| AVG Volume (30 Days) | ★ 3.9M | 1.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.55 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $692,845,000.00 | $216,105,000.00 |
| Revenue This Year | $14.30 | $21.35 |
| Revenue Next Year | $10.15 | $37.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.38 | 8.72 |
| 52 Week Low | $4.71 | $4.14 |
| 52 Week High | $17.39 | $9.91 |
| Indicator | REAL | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 38.92 | 38.46 |
| Support Level | $8.05 | $5.73 |
| Resistance Level | $11.48 | $7.76 |
| Average True Range (ATR) | 0.69 | 0.29 |
| MACD | -0.21 | -0.03 |
| Stochastic Oscillator | 10.64 | 12.18 |
The RealReal Inc is an online marketplace for authenticated, resale luxury goods, providing an end-to-end service that unlocks supply and creates a trusted, curated marketplace for buyers globally. Since its inception, the company has cultivated a loyal and engaged consignor and buyer base through continuous investment in its technology platform, logistics infrastructure, brand and people. It offers a wide selection of authenticated, mainly pre-owned luxury goods bearing the brands of thousands of luxury and premium designers, including Cartier, Chanel, Christian Dior, Gucci, Hermes, Louis Vuitton and Rolex. The company offers products across women's fashion, men's fashion, jewelry, and watches, promoting the recirculation of luxury goods and contributing to a more sustainable world.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.